EUVIMEDSkopri EUVIMED
VergleichsstudieOpen access · CC BY-NC-ND 4.0

Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients

Lyra P Beltran iD, Jamie Benken iD, Jonathan Jou, Enrico Benedetti iD, Hokuto Nishioka, Enas Alamreia, Rachel M Belcher iD, Scott T Benken iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15432 ↗

At a glance

Vergleichsstudie in Clinical Transplantation, 2024. Written by Lyra P Beltran and 7 co-authors. Institution: Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA. Major MEDLINE topics: Kidney Transplantation, Vasoconstrictor Agents, Phenylephrine, Angiotensin II. Cited 7 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Angiotensin II (ATII) maintains blood pressure via RAAS with a beneficial adverse effect profile versus catecholamines and phenylephrine. Head‐to‐head data comparing ATII to phenylephrine are lacking regarding renal allograft function, hemodynamic efficacy, and safety within the perioperative period of kidney transplantation.

Methods

This single‐center, retrospective study included adult kidney transplant recipients who received continuous infusions of ATII or phenylephrine within a 24‐h perioperative period as a first‐line vasopressor according to an institutional algorithm. The primary endpoint was allograft function. Secondary endpoints were hemodynamic efficacy and adverse effects.

Results

Among 105 patients, there was no significant difference in IGF ( p = 0.545), SGF ( p = 0.557), or DGF ( p = 0.878) between patient cohorts. In the 34 patients with cold ischemia time (CIT) > 14‐h, IGF was higher ( p = 0.013) and DGF ( p = 0.045) was lower in the ATII cohort versus phenylephrine. In all patients, ATII was associated with a decreased need for additional vasopressor agents ( p < 0.001). Adverse effect profiles were similar between cohorts ( p > 0.05).

Conclusion

Among kidney transplant recipients, ATII may be a suitable first‐line alternative compared with phenylephrine in the perioperative period for hypotension management with a reduced need for additional vasopressor support. Allograft benefits were observed in patients with prolonged CIT.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationVasoconstrictor AgentsPhenylephrineAngiotensin IIGraft SurvivalHumansFemaleMaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisAdultKidney Failure, ChronicGlomerular Filtration RatePostoperative ComplicationsKidney Function TestsPerioperative CareGraft RejectionRisk FactorsInfusions, Intravenous

Author keywords

Giaprezaangiotensin IIkidney transplantphenylephrineshockvasopressors

Substances

Vasoconstrictor AgentsPhenylephrineAngiotensin II

Authors and institutions

  • Department of Pharmacy Practice, University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA.
  • Department of Surgery, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
  • Department of Surgery, Division of Transplantation, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
  • Division of Clinical Anesthesiology, Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA.
  • University of Illinois Chicago College of Pharmacy, Denver, Colorado, USA.

ORCID profiles: Lyra P Beltran, Jamie Benken, Enrico Benedetti, Rachel M Belcher, Scott T Benken

Cite

APA

Beltran, L. P., Benken, J., Jou, J., Benedetti, E., Nishioka, H., Alamreia, E., Belcher, R. M., & Benken, S. T. (2024). Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15432

Vancouver

Beltran LP, Benken J, Jou J, Benedetti E, Nishioka H, Alamreia E, et al. Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.15432

BibTeX
@article{Beltran2024,
  author = {Beltran, Lyra P and Benken, Jamie and Jou, Jonathan and Benedetti, Enrico and Nishioka, Hokuto and Alamreia, Enas and Belcher, Rachel M and Benken, Scott T},
  title = {Efficacy and Safety of Perioperative Angiotensin II Versus Phenylephrine as a First‐Line Continuous Infusion Vasopressor in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15432}
}
Start for free →